The Therapeutics Initiative is at arms length from government and other vested interest groups. Our function is unbiased review and dissemination of therapeutic evidence. Assessments apply to most patients; exceptional patients require exceptional approaches. We are committed to evaluate the effectiveness of our educational activities using the Pharmacare database without identifying individual physicians, pharmacies or patients.
We are bombarded with suggestions as to what should be our drug of first choice in the management of patients with documented elevated blood pressure. Is it appropriate to choose randomly from the wide array of available drugs, or is there a way to rationally pick the drug which is most likely to benefit our patients? By setting up a hierarchy of the issues which are most important, and compiling and critically appraising the presently available evidence, it is possible to narrow the choice to one or two drugs (see picture). The issues that are significant in descending order of importance include: evidence of effectiveness in decreasing the complications associated with hypertension, efficacy in lowering blood pressure, tolerability, convenience of dosing, and cost.
Studies to answer this question must be randomized, controlled, and double-blind to prevent bias and must be large and of sufficient duration. In 1990 a meta-analysis of the 14 trials which met defined criteria was published.(1) This analysis (mean age 52 years, 53% male), demonstrated that a 5-6 mm Hg decrease in diastolic blood pressure produced a 14% reduction in coronary heart disease, and a 42% reduction in cerebrovascular accidents over a 5 year follow-up period. Since 1990, five additional trials have been published. These trials have confirmed and strengthened the original meta-analysis, and demonstrated a greater relative and absolute risk reduction, particularly for coronary artery disease in the elderly (2) plus the benefit of treating isolated systolic hypertension.(3) Most of the patients in these trials received thiazide diuretics as the only drug or as a component of the treatment. We therefore have compelling evidence of the effectiveness of this class of drugs in reducing morbidity and mortality in patients of all ages and types of hypertension. Beta blockers have also been studied as a single agent, but have not consistently shown an equal benefit: in a trial comparing atenolol with hydrochlorothiazide/amiloride, both drugs lowered blood pressure to the same degree but only the thiazide was associated with a decreased risk of stroke and coronary events. (4) We therefore cannot assume that an equal reduction in blood pressure will be associated with an equal benefit. Other classes of antihypertensives have not been assessed in effectiveness trials.
There are many trials comparing efficacy, but the most relevant trial is the TOMHS study. (5) In this study with an average 4.4 years of follow-up 5 antihypertensive drugs and placebo were compared in 902 patients with mild hypertension. The drugs and daily doses used were thiazide-like diuretic, (chlorthalidone, 15 mg), beta-blocker, (acebutolol, 400 mg), ACE inhibitor, (enalopril 5 mg), alpha1-antagonist, (doxazosin, 2 mg), and calcium antagonist, (amlodipine, 5 mg). The blood pressure lowering efficacy of all the five drugs was similar and greater than placebo. For chlorthalidone, but not for the other drugs, left ventricular mass declined more than for participants given placebo.
In the same trial a significant improvement in quality-of-life indexes was seen with acebutolol and chlorthalidone but not with the other drugs. The incidence of impotence was greater in men assigned to placebo than those assigned to drug treatment.
The preferred regimen for chronic preventive therapy is once daily dosing. All thiazide and thiazide-like drugs should be prescribed only once daily in the morning. There are significant cost differences.(see Table and Therapeutics Letter 8). Hydrochlorothiazide is the least expensive of all antihypertensive drugs available in B.C.
Using recommended low-dose regimens (table) the incidence of hypokalemia is small (1% of patients in the SHEP study had K+ below 3.2 meq/L).(3) In patients who develop hypokalemia a K+-sparing diuretic should be added (see Table). Do not prescribe K+ supplements; they are inconvenient and expensive. The small increase in total cholesterol (2.5%) and triglycerides seen in some studies was not seen in the TOMHS study (5) and has not been proven to have any adverse consequences. The hyperglycemic effect is also small and did not have any consequences in the SHEP study in which at least 10% of patients had NIDDM on entry.3 Thiazides can be safely used for the treatment of hypertension in NIDDM, except in patients where significantly worsened glucose control has been proven. Elevations in uric acid seen with thiazides are innocuous; thiazides should not be used in patients who develop recurrent gout with thiazide therapy.
Thiazides and indapamide have direct vasorelaxant effects on resistance vessels. The thiazides are acting on calcium activated potassium channels and indapamide is acting as a calcium antagonist. (6) Therefore indapamide cannot be used interchangeably with the thiazides. The diuretic action of these drugs may have only minor importance in the overall antihypertensive effect.
Based on the evidence available at this time and using criteria of effectiveness and cost, thiazides are clearly the drug of first choice. Based on the criteria of efficacy, tolerability and convenience, thiazides are equivalent to or better than all other drugs. Therefore, thiazides are the drug of first choice for most uncomplicated hypertensive patients. There will be a proportion of patients (20-25%) where thiazides are proven ineffective or inappropriate. In these patients or in patients requiring more than one drug, other drugs must be substituted or added. These other drugs will be discussed in Therapeutics Letter 8.
|Diuretic||Trade Name||Usual Dosage Range||Daily Cost*
Chlorthalidone 50 mg
|12.5 - 25 mg daily
12.5 - 25 mg daily
|0.3 - 0.6
1.2 - 2.4
|Bendroflumethiazide 2.5 mg
Indapamide 2.5 mg
|1.25 - 2.5 mg daily
2.5 mg daily
|6.6 - 13.3
|HCTZ (25 mg)/triamterene (50 mg)
HCTZ (50 mg)/amiloride (5 mg)
HCTZ (25 mg)/spironolactone (25 mg)
Triamterene (50, 100 mg)
Amiloride (5 mg)
Spironolactone (25, 100 mg)
|1/2 - 1 tablet daily
1/4 - 1/2 tablet daily
1/2 - 1 tablet daily
25 - 50 mg daily
2.5 - 5 mg daily
25 - 100 mg daily
|2.5 - 5.0
5.9 - 11.9
5.6 - 11.2
9.9 - 13.1
15.2 - 30.4
8.8 - 27.6
* Least expensive available formulation in BC, 1993
Collins R, Peto R, MacMahon S, et al. Epidemiology, blood pressure, stroke and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. A meta-analysis of outcome trials in elderly hypertensives. J of Hypertension, 1992;10:1103-9.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991;265:3255-64.
Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J. 1992;304:405-12.
Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study Final Results. JAMA. 1993;270:713-724.
Calder JA, Schachter M, Sever PS. Ion Channel Involvement in the Acute Vascular Effects of Thiazide Diuretics and Related Compounds. J. Pharmacol. Exp. Ther. 1993;265:1175-80.
Please send feedback!
Back to Therapeutics Letter.
Back to the Therapeutics Initiative Home Page.
©Therapeutics Initiative. Last updated: November 28, 1996.